Pediatric cancers

ACE Cash Express Helps Children Battling Childhood Cancer Raising Over $31,000 for Alex's Lemonade Stand Foundation

Retrieved on: 
Thursday, July 22, 2021
Pediatric cancers, Childhood, Childhood cancer, Alex's Lemonade Stand Foundation, Lemonade Stand, Lemonade, Articles, United States, The Malvern School

DALLAS, July 22, 2021 /PRNewswire/ -- ACE Cash Express (ACE), a Populus Financial Group brand , raised $31,145 for Alex's Lemonade Stand Foundation during their annual fundraising event, the Give A Little Campaign.

Key Points: 
  • DALLAS, July 22, 2021 /PRNewswire/ -- ACE Cash Express (ACE), a Populus Financial Group brand , raised $31,145 for Alex's Lemonade Stand Foundation during their annual fundraising event, the Give A Little Campaign.
  • Alex's Lemonade Stand Foundation (ALSF) is changing the lives of children with cancer by funding impactful research, raising awareness, supporting families and empowering everyone to help cure childhood cancer.
  • By supporting Alex's Lemonade Stand Foundation, ACE is funding research for better diagnostics and treatment for pediatric cancer.
  • Alex's Lemonade Stand Foundation (ALSF) emerged from the front yard lemonade stand of 4-year-old Alexandra "Alex" Scott, who was fighting cancer and wanted to raise money to find cures for all children with cancer.

TRIOSE Named a Top Fundraiser by Alex’s Lemonade Stand Foundation

Retrieved on: 
Tuesday, July 20, 2021
Albums, Pediatric cancers, Business simulation games, Childhood cancer, Lemonade, Stand

WYOMISSING, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- TRIOSE, Inc., the leading provider of intelligent healthcare supply chain solutions, today announced it was named a Top Fundraiser by Alex’s Lemonade Stand Foundation, a non-profit organization dedicated to fighting childhood cancer. This is the fourth consecutive year that TRIOSE has been awarded this designation.

Key Points: 
  • WYOMISSING, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- TRIOSE, Inc. , the leading provider of intelligent healthcare supply chain solutions, today announced it was named a Top Fundraiser by Alexs Lemonade Stand Foundation, a non-profit organization dedicated to fighting childhood cancer.
  • Alexs Lemonade Stand is making a difference in the fight against childhood cancer, and our partnership with this vital organization enables TRIOSE to realize our mission of making a difference in healthcare.
  • TRIOSE is an ideal partner for Alexs Lemonade Stand Foundation because their support is so broad, said Jay Scott, executive director of Alexs Lemonade Stand.
  • Each year, the company pledges to donate to Alexs Lemonade Stand a percentage of savings realized by its clients through TRIOSE programs.

Bionano’s Optical Genome Mapping for Acute Lymphoblastic Leukemia Subjects at the University Hospitals Leuven, Belgium, Has Faster Turnaround Time, Higher Success Rates and Lower Cost per Sample Compared to Traditional Methods

Retrieved on: 
Monday, July 19, 2021
Laboratory techniques, Pediatric cancers, Leukemia, Ogm, Acute lymphoblastic leukemia, Assay, Branches of biology, Medical specialties, Academic disciplines

An assay was developed for whole genome analysis of acute lymphoblastic leukemia (ALL) subjects which, relative to traditional methods, resulted in a workflow with significantly faster turnaround time, higher success rates, and lower cost per sample.

Key Points: 
  • An assay was developed for whole genome analysis of acute lymphoblastic leukemia (ALL) subjects which, relative to traditional methods, resulted in a workflow with significantly faster turnaround time, higher success rates, and lower cost per sample.
  • OGM showed 100% concordance with the traditional methods with no false positives.
  • Dr. Dewaele summarized that their hospital plans to develop more OGM-based assays for other types of leukemias.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference

Retrieved on: 
Friday, July 9, 2021
Pediatric cancers, Cancer, Childhood cancer

Members of the Salarius management team will be available to participate in one-on-one virtual meetings with registered investors and pharmaceutical companies.

Key Points: 
  • Members of the Salarius management team will be available to participate in one-on-one virtual meetings with registered investors and pharmaceutical companies.
  • Following the conclusion of the event, a recording of Mr. Arthurs presentation will be available under Events & Presentations in the Investors section of the Companys website at http://www.salariuspharma.com .
  • Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options.
  • Salarius lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options.

Global Brain Tumor Diagnosis & Treatment Market Could Exceed $880 Million By 2027

Retrieved on: 
Tuesday, June 29, 2021
Brain tumor, Cancer, Pediatric cancers, Health, Clinical medicine, Oncology, Anatomical pathology

According to the National Brain Tumor Society, there are around 700,000 Americans living with primary brain cancer, and approximately 84,170 people are estimated to receive a primary brain tumor diagnosis in 2021.

Key Points: 
  • According to the National Brain Tumor Society, there are around 700,000 Americans living with primary brain cancer, and approximately 84,170 people are estimated to receive a primary brain tumor diagnosis in 2021.
  • Reports show that 2 markets in the brain tumor segment: The Brain Tumor Diagnostics and the Brain Tumor Drugs markets.
  • While a report from Fortune Business Insights added that: "The global brain tumor drugs market size was USD 2.35 billion in 2020.
  • The ResearchAndMarket report continued: "The U.S. Market is Estimated at $145.3 Million, While China is Forecast to Grow at 11.2% CAGR The Brain Tumor Diagnosis and Treatment market in the U.S. is estimated at US$145.3 Million in the year 2020.

Global Brain Tumor Diagnosis & Treatment Market Could Exceed $880 Million By 2027

Retrieved on: 
Tuesday, June 29, 2021
Brain tumor, Cancer, Pediatric cancers, Health, Clinical medicine, Oncology, Anatomical pathology

According to the National Brain Tumor Society, there are around 700,000 Americans living with primary brain cancer, and approximately 84,170 people are estimated to receive a primary brain tumor diagnosis in 2021.

Key Points: 
  • According to the National Brain Tumor Society, there are around 700,000 Americans living with primary brain cancer, and approximately 84,170 people are estimated to receive a primary brain tumor diagnosis in 2021.
  • Reports show that 2 markets in the brain tumor segment: The Brain Tumor Diagnostics and the Brain Tumor Drugs markets.
  • While a report from Fortune Business Insights added that: "The global brain tumor drugs market size was USD 2.35 billion in 2020.
  • The ResearchAndMarket report continued: "The U.S. Market is Estimated at $145.3 Million, While China is Forecast to Grow at 11.2% CAGR The Brain Tumor Diagnosis and Treatment market in the U.S. is estimated at US$145.3 Million in the year 2020.

St. Baldrick's Works to Give Kids with Cancer More Than Five Years

Retrieved on: 
Tuesday, June 15, 2021
Cancer, Pediatric cancers, Health, Neoplasms, Oncology, Cancer in cats, Cancer in dogs, Osteosarcoma, Sarcoma, Bone tumor, Childhood cancer, Breast cancer

But, according to the National Cancer Institute, the five-year survival rate for childhood cancers has risen to 84% overall.

Key Points: 
  • But, according to the National Cancer Institute, the five-year survival rate for childhood cancers has risen to 84% overall.
  • That is meaningful in scientific terms, but it's just not good enough for a child with cancer.
  • While hitting the five-year milestone is worth celebrating, some will die later, either of their cancer or the effects of their treatment.
  • But, for other types of childhood cancer like osteosarcoma, a cancer of the bone treatment is not much different today than it was decades ago.

Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib

Retrieved on: 
Monday, June 14, 2021
Pediatric cancers, Childhood, Pediatrics, Childhood cancer, Cancer, Health, Medicine, Pediatric psychology

We are very pleased to partner with Oncoheroes on these pediatric cancer programs to help address historically underserved, rare childhood cancers.

Key Points: 
  • We are very pleased to partner with Oncoheroes on these pediatric cancer programs to help address historically underserved, rare childhood cancers.
  • Under the terms outlined in the binding terms sheets, Oncoheroes will acquire global, exclusive rights to fund and conduct further clinical development of both dovitinib and stenoparib in pediatric cancer.
  • Under the dovitinib term sheet, Oncoheroes will take responsibility for pediatric cancer clinical development activities.
  • If Allarity does not re-acquire the pediatric field rights, it will further receive certain clinical/regulatory milestone payments and royalties on sales of stenoparib in the pediatric cancer market from Oncoheroes.

European Hematology Association - Clinical Trial Efficacy of CAR-T Therapy in Patients with Diffuse Large B-cell Lymphoma Is Mirrored in the Real World

Retrieved on: 
Friday, June 11, 2021
Medicine, Clinical medicine, Branches of biology, Lymphoma, Gene therapy, Pediatric cancers, Chimeric antigen receptor T cell, Leukemia, Clinical trial, Kite Pharma, Cancer immunotherapy

In this study, we aimed to analyze patient characteristics and clinical outcome of 537 patients with diffuse large B-cell lymphoma who were registered in the DESCAR-T database.

Key Points: 
  • In this study, we aimed to analyze patient characteristics and clinical outcome of 537 patients with diffuse large B-cell lymphoma who were registered in the DESCAR-T database.
  • Approximately 50 new patients were registered each month, demonstrating the success of CAR-T therapy.
  • Of the registered patients, CAR-T cells were ordered for 607 patients and 550 had been infused.
  • In conclusion, our analysis of the DESCAR-T registry confirmed the clinical trial efficacy of CAR-T therapy in the real world.

European Hematology Association - Clinical Trial Efficacy of CAR-T Therapy in Patients with Diffuse Large B-cell Lymphoma Is Mirrored in the Real World

Retrieved on: 
Friday, June 11, 2021
Medicine, Clinical medicine, Branches of biology, Lymphoma, Gene therapy, Pediatric cancers, Chimeric antigen receptor T cell, Leukemia, Clinical trial, Kite Pharma, Cancer immunotherapy

In this study, we aimed to analyze patient characteristics and clinical outcome of 537 patients with diffuse large B-cell lymphoma who were registered in the DESCAR-T database.

Key Points: 
  • In this study, we aimed to analyze patient characteristics and clinical outcome of 537 patients with diffuse large B-cell lymphoma who were registered in the DESCAR-T database.
  • Approximately 50 new patients were registered each month, demonstrating the success of CAR-T therapy.
  • Of the registered patients, CAR-T cells were ordered for 607 patients and 550 had been infused.
  • In conclusion, our analysis of the DESCAR-T registry confirmed the clinical trial efficacy of CAR-T therapy in the real world.